Cannabis can be consumed via a number of methods- smoking, vaping, topical application, edibles, etc. However, none of these methods may come in handy to bring immediate relief to patients with asthma or other respiratory conditions. Therefore, Israel-based scientists have created cannabis inhalers that should hit the markets this year.
The method is still being tested by two Israeli companies – Panaxia Pharmaceuticals and Rafa Pharmaceuticals – working in collaboration to bring the product in the market at the earliest.
A few months ago Panaxia had released information about the operation of new clinical trials at the country’s Ministry of Health. The intention behind conducting these clinical trials is to, of course, get a better understanding of the efficacy of marijuana via inhalers with accurately measured controlled doses.
Registrations for these clinical trials are still open. So anyone suffering from asthma or other respiratory issues is free to enroll and experience the inhaler even before they are in the medical stores near you.
“The inhaler will provide patients that are unable or unwilling to smoke the right to be treated consistently and precisely,” Dr. Dadi Segal, Panaxia’s CEO, was quoted as saying to a leading newspaper.
All cannabis inhalers will sport a vaporizer, allowing medical patients to fill in their desired doses of a cannabis extract or concentrate, which could then be inhaled.
Patients will be able to purchase the inhalers only through a medical specialist’s prescription or recommendation.
Israel has been making a lot of changes in its marijuana policies and laws of late, especially after an increase in support for PM Netanyahu’s rival pro-cannabis and quasi-libertarian Zehut party, led by firebrand former Likud MK Moshe Feiglin.
The launch of the cannabis inhalers should come as a boon for patients with debilitating or near-debilitating respiratory conditions.
